…lished paper on the topic used the descriptor ‘benign/burnt-out MS’, which compounded one controversial term with another (McFaul et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e960). The study was a health database analysis, so the term was less about clinical measures than about checkboxes; the goal was to identify people who could safely stop their disease-modifying therapy (DMT). As such, benign/burned-out MS was defined as an RRMS patient wit…

…nadian-virtual-care-priorities-covid-19/enhancing-access-principle-based-recommendations-equity/based-recommendations-equity-en.pdf). For example, a NARCOMS survey found that telehealth video visits were less common among disadvantaged groups, such as the elderly and those with greater impairments (Marrie et al. Neurol Clin Pract 2022;12:223-233). Telephone contact can be made in rural areas where videoconferencing is unavailable but generally pro…

…failed to meet its primary endpoint in its two EVOLUTION phase III trials (www.emdgroup.com/en/news/evobrutinib-phase-lll.html). The annualized relapse rate for evobrutinib in the two studies (0.11, 0.15) was similar to what was seen with teriflunomide (0.11, 0.14). Evobrutinib performed as expected: the unadjusted ARR was the same in the phase II trial (0.11 vs. 0.14 for DMF) (Montalban et al. N Engl J Med 2019;380:2406-2417) and the same (0.11)…